Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 4Gastrointestinal 1

Conditions

Neoplasms 13Neoplasm Metastasis 6Adenocarcinoma 4Carcinoma 2

Interventions

Oxaliplatin 14Gemcitabine 13Fluorouracil 11Leucovorin 9Capecitabine 9pembrolizumab 7Docetaxel 7Irinotecan 6Paclitaxel 5zolbetuximab 4regorafenib 4Trastuzumab 4Radiotherapy 4Pemetrexed 4S 1 (combination) 3Ramucirumab 3Nivolumab 3Drug Therapy 3Cisplatin 3Bevacizumab 3vandetanib 2tislelizumab 2sargramostim 2lenvatinib 2icotinib 2camrelizumab 2bemarituzumab 2apatinib 2Phlebotomy 2Esophagectomy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Adenocarcinoma × regorafenib × Tumor-Agnostic × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated
89 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT02773524 2022-01-13

INTEGRATEIIa

Australasian Gastro-Intestinal Trials Group

Phase 3 Unknown
250 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT01929616 2019-06-25

RegARd-C

Jules Bordet Institute

Phase 2 Completed
141 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡